Cite
Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemia.
MLA
Aldoss, Ibrahim, et al. “Venetoclax and Hypomethylating Agents in TP53‐mutated Acute Myeloid Leukaemia.” British Journal of Haematology, vol. 187, no. 2, Oct. 2019, pp. e45–48. EBSCOhost, https://doi.org/10.1111/bjh.16166.
APA
Aldoss, I., Zhang, J., Pillai, R., Shouse, G., Sanchez, J. F., Mei, M., Nakamura, R., Stein, A. S., Forman, S. J., Marcucci, G., & Pullarkat, V. (2019). Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemia. British Journal of Haematology, 187(2), e45–e48. https://doi.org/10.1111/bjh.16166
Chicago
Aldoss, Ibrahim, Jianying Zhang, Raju Pillai, Geoffrey Shouse, James F. Sanchez, Matthew Mei, Ryotaro Nakamura, et al. 2019. “Venetoclax and Hypomethylating Agents in TP53‐mutated Acute Myeloid Leukaemia.” British Journal of Haematology 187 (2): e45–48. doi:10.1111/bjh.16166.